不同剂量结核病DNA疫苗的电转染免疫原性研究

doi:10.3969/j.issn.1000-6621.2014.06.004

摘要/Abstract

摘要： 目的研究不同剂量结核病DNA疫苗电转染后的免疫原性。方法 40只BALB/c小鼠通过随机数字表法分为8组，每组5只。其中4组分别用100 μl 生理盐水和10 μg、50 μg、100 μg结核分枝杆菌Ag85A DNA肌内注射免疫小鼠；另4组用100 μl 生理盐水和10 μg、50 μg、100 μg Ag85A DNA肌内注射加电转染免疫小鼠。每2周免疫1次，共3次。最后1次免疫后2周杀死小鼠。用ELISA方法检测小鼠脾细胞培养上清液中γ干扰素（IFN-γ）和白细胞介素4（interleukin 4，IL-4）水平；用流式细胞术检测小鼠外周血单个核细胞（PBMC）分泌IFN-γ的辅助性T细胞（helper T cell，Th）1细胞百分比、分泌IL-4 的Th2细胞百分比，以及Th1与Th2的细胞比值。用SAS 9.2软件处理数据，实验数据以“x±s”表示，对有关数据进行两因素析因设计的方差分析，两两比较采用t检验，P<0.05为差异有统计学意义。结果免疫结束后2周，小鼠脾淋巴细胞分泌IFN-γ水平，50 μg ［（646.05±342.53）pg/ml］和100 μg Ag85A DNA肌内注射组［(738.61±372.68) pg/ml］显著高于生理盐水组［（1.73±3.88）pg/ml］（t值分别为4.065、4.647，P值均＜0.05）和10 μg Ag85A DNA组［（87.83±120.82）pg/ml］（t值分别为3.513、4.094，P值均<0.05）；10 μg Ag85A DNA电转染组［（357.06±105.18）pg/ml］显著高于生理盐水组（t=2.247，P<0.05），高于100 μg Ag85A DNA电转染组［（86.08±135.73）pg/ml］，但差异无统计学意义（t=1.706，P＞0.05）；50 μg Ag85A DNA电转染组［（648.60±439.41）pg/ml］显著高于生理盐水组（t=4.081，P<0.05）和100 μg Ag85A DNA电转染组（t=3.539，P<0.05）。与直接肌内注射组IFN-γ水平［（87.83±120.82）pg/ml］比较，10 μg Ag85A DNA电转染组增高3倍［（357.06 pg/ml）/（87.83 pg/ml）］；50 μg Ag85A DNA肌内注射组［（646.05±342.53）pg/ml］与电转染组［（648.60±439.41）pg/ml］比较，差异无统计学意义（t=－0.016，P＞0.05）；100 μg Ag85A DNA电转染组［（86.08±135.73）pg/ml］较肌内注射组［(738.61±372.68) pg/ml］降低88.35%（t=－4.105，P<0.05）。小鼠PBMC分泌IFN-γ 的Th1细胞百分比，不同剂量Ag85A DNA肌内注射组［10 μg Ag85A DNA：（1.39±0.84）%；50 μg Ag85A DNA：（1.55±0.33）%；100 μg Ag85A DNA：（2.13±0.47）%］和DNA电转染组［10 μg Ag85A DNA：（1.42±0.47）%；50 μg Ag85A DNA：（1.88±0.51）%；100 μg Ag85A DNA：（1.43±0.68）%］均高于生理盐水组［（0.65±0.31）%］（t值分别为2.002、2.431、4.015、2.084、3.332和2.105，P值均＜0.05），但不同剂量Ag85A DNA电转染组与肌内注射组之间差异均无统计学意义（t值分别为0.081、0.901和－1.91，P值均＞0.05）。小鼠PBMC分泌IL-4的Th2细胞百分比，不同剂量Ag85A DNA肌内注射组［10 μg Ag85A DNA：（1.42±1.18）%；50 μg Ag85A DNA：（1.14±0.78）%；100 μg Ag85A DNA：（1.24±0.76）%］和DNA电转染组［10 μg Ag85A DNA：（1.19±1.09）%；50 μg Ag85A DNA：（2.06±0.96）%；100 μg Ag85A DNA：（1.47±0.65）%］均显著低于生理盐水电转染组［（4.14±2.55）%］（t值分别为－3.392、－3.738、－3.616、－3.676、－2.599和－3.325，P值均＜0.05），但不同剂量 DNA肌内注射组与DNA电转染组之间差异无统计学意义（t值分别为0.284、－1.139和－0.292，P值均＞0.05）。结论 DNA电转染免疫可以增强低剂量DNA疫苗的免疫应答，使用少量的DNA疫苗就可以产生较好的免疫效果。

关键词: 分枝杆菌, 结核, 疫苗, DNA, 电穿孔, 免疫

Abstract: Objective To study the immunogenicity of different dosages DNA vaccines from Mycobacterium tuberculosis medicated by electroporation. Methods Twenty female BALB/c mice were immunized intramuscularly with saline, 10 μg Ag85A DNA, 50 μg Ag85A DNA and 100 μg Ag85A DNA for three times at two-week intervals, respectively. Twenty female BALB/c mice were medicated intramuscularly by electroporation with saline, 10 μg Ag85A DNA, 50 μg Ag85A DNA and 100 μg Ag85A DNA for 3 times at two-week intervals, respectively. There were 5 mice each group. Mice were sacrificed at 2 weeks after the final immunization respectively. The levels of IFN-γ and IL-4 in the culture supernatants of splenic lymphocytes were measured with enzyme-linked immunosorbent assay (ELISA). The ratio of CD4⁺ T cells expressing IFN-γ (Th1) and IL-4 (Th2) in whole blood was detected by flow cytometry. Data were expressed as means and standard deviations. Statistical significance between each group was calculated using two factors factorial design ANOVA followed by compared with t test using SAS 9.2 software and a P-value of <0.05 was considered to be statistically significant. Results At 2 weeks after the final immunization, IFN-γ levels in splenocyte culture supernatant in 50 μg DNA (646.05±342.53) pg/ml and 100 μg DNA intramuscular injection group (738.61±372.68) pg/ml was significantly higher than that in saline (1.73±3.88) pg/ml (t=4.065 and 4.647, all P<0.05) and 10 μg DNA intramuscular injection group (87.83±120.82) pg/ml (t=3.513 and 4.094, all P<0.05); IFN-γ level in splenocyte culture supernatant in 10 μg DNA electroporation group (357.06±105.18) pg/ml was significantly higher than that in saline (t=2.247, P<0.05)，and higher than that in 100 μg DNA electroporation group (86.08±135.73) pg/ml，but the difference was not statistically significant(t=1.706, P>0.05). 50 μg DNA electroporation group (648.60±439.41) pg/ml was significantly higher than that in saline(t=4.081, P<0.05) and 100 μg DNA electroporation group(t=3.539, P<0.05); compared with intramuscular injection group, IFN-γ levels of 10 μg DNA electroporation group increased 3 times (357.06 pg/ml)/(87.83 pg/ml); that of 50 μg DNA electroporation group had no significant change (t=－0.016, P＞0.05); that in 100 μg DNA electroporation group declined 88.35% (t=－4.105, P<0.05). Percentage of Th1 cells secreted IFN-γ in different dosages of intramuscular DNA (10 μg Ag85A DNA：(1.39±0.84)%, 50 μg Ag85A DNA：(1.55±0.33)%, 100 μg Ag85A DNA：(2.13±0.47)%) and DNA electroporation groups (10 μg Ag85A DNA：(1.42±0.47)%, 50 μg Ag85A DNA：(1.88±0.51)%, 100 μg Ag85A DNA：(1.43±0.68)%) were higher than that in saline group (0.65±0.31)% (t=2.002, 2.431, 4.015, 2.084, 3.332 and 2.105, all P<0.05), there has no statistical difference between doages DNA electroporation groups and intramuscular injection groups (t=0.081, 0.901 and －1.91, all P>0.05). Percentage of Th2 cells secreted IL-4 in different dosages of intramuscular DNA (10 μg Ag85A DNA：(1.42±1.18)%, 50 μg Ag85A DNA：(1.14±0.78)%, 100 μg Ag85A DNA：(1.24±0.76)%) and DNA electroporation groups (10 μg Ag85A DNA：(1.19±1.09)%, 50 μg Ag85A DNA：(2.06±0.96)%, 100 μg Ag85A DNA：(1.47±0.65)%) were higher than that in saline electroporation group (4.14±2.55)% (t=－3.392, －3.738, －3.616, －3.676, －2.599 and －3.325, all P<0.05), there was no statistically significant difference between doages DNA electroporation groups and intramuscular injection groups(t=0.284, －1.139 and －0.292, all P>0.05). Conclusion The results suggest that lower doses of DNA immunization by electroporation could improve immune response, using a small amount of DNA vaccine can produce good immune effect.

Key words: Mycobacterium tuberculosis, Vaccines, DNA, Electroporation, Immunity

梁艳，肖漓，白雪娟，高钰，阳幼荣，张晓燕，陈丹，王兰，史迎昌，张俊仙，李忠明，吴雪琼. 不同剂量结核病DNA疫苗的电转染免疫原性研究[J]. 中国防痨杂志, 2014, 36(6): 424-428. doi: 10.3969/j.issn.1000-6621.2014.06.004

LIANG Yan, XIAO Li, BAI Xue-juan, GAO Yu, YANG You-rong, ZHANG Xiao-yan, CHEN Dan, WANG Lan, SHI Ying-chang, ZHANG Jun-xian, LI Zhong-ming, WU Xue-qiong. Immunogenicity of different dosage DNA vaccine from Mycobacterium tuberculosis medicated by electroporation[J]. Chinese Journal of Antituberculosis, 2014, 36(6): 424-428. doi: 10.3969/j.issn.1000-6621.2014.06.004

参考文献

［1］Glaziou P, Falzon D, Floyd K, et al. Global epidemiology of tuberculosis. Semin Respir Crit Care Med, 2013, 34(1):3-16.
［2］Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol，1997，15:617-648.
［3］Meyer J, McShane H. The next years for tuberculosis vaccines: do we have the right plans in place? Expert Rev Vaccines，2013，12(4):443-451.
［4］MacGregor R, Boyer J, Ugen K, et al. First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis，1998，178(1): 92-100.
［5］Liu MA, McClements W, Ulmer JB, et al. Immunization of non-human primates with DNA vaccine. Vaccine，1997，15(8): 909-912.
［6］Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine，1999，17 (22): 2826-2829.
［7］Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol，2000，18:927-974.
［8］Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol，2011，23(3):421-429.
［9］Liu KH, Ascenzi MA, Bellezza CA, et al. Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks. J Virol，2011，85(10):4853-4862.
［10］Barbon CM1, Baker L, Lajoie C, et al. In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine，2010，28(50):7852-7864.
［11］Zupanic A, Corovic S, Miklavcic D, et al. merical optimization of gene electrotransfer into muscle tissue. Biomed Eng Online，2010，9:66.
［12］Denis O, Tanghe A, Palfliet K, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T cell epitopic repertoire broader than that stimulated by M. tuberculosis H37Rv infection. Infect Immun，1998，6(4):1527-1533.
［13］吴雪琼，张俊仙，李洪敏，等. 结核分枝杆菌Ag85A DNA 疫苗免疫治疗作用的研究. 中国免疫学杂志，2002，18(1):17-22.
［14］Liang Y, Wu XQ, Zhang JX, et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. Vaccine，2008，26(35):4536-4540.
［15］Liang Y, Wu X, Zhang J, et al. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. Scand J Immunol，2011，74(1):42-46.
［16］梁艳，吴雪琼，张俊仙，等. 结核分枝杆菌Ag85A DNA 疫苗抗结核作用的研究. 中国防痨杂志，2012，34(3):181-183.
［17］Ha SJ, Jeon BY, Kim SC, et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Therapy，2003，10(18):1592-1599.
［18］Lowrie DB, Tascon RE, Bonato VLD, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature，1999，400(6741):269-271.
［19］Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med，1996，2(8):893-898.
［20］华瑞，华芳，陈海美，等. 电穿孔法增强HBV DNA疫苗免疫效果的评价. 吉林大学学报(医学版)，2008，34(2):347-350.
［21］李鼎锋，张玉伟，李海山，等. 体内电穿孔对报告基因表达和HIV Gag DNA 疫苗诱导的免疫反应的影响. 中华微生物学和免疫学杂志，2006，26(11):1038-1041.
［22］Derrick SC, Repique C, Snoy P, et al. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun，2004，72(3):1685-1692.
［23］Green AM, Difazio R, Flynn JL. IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol，2013，190(1):270-277.
［24］Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol，2001，19:93-129.
［25］Munk ME, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J，1995，20(Suppl):S668-675.

[1]	胡一凡, 杜博平, 吴亚东, 朱传智, 张蓝月, 贾红彦, 孙琦, 潘丽萍, 张宗德, 李自慧. Mce4C蛋白参与结核分枝杆菌摄取利用胆固醇的实验研究[J]. 中国防痨杂志, 2025, 47(4): 444-453.
[2]	王颖超, 刘唯夷, 姬秀秀, 尚雪恬, 贾红彦, 张蓝月, 孙琦, 杜博平, 朱传智, 潘丽萍, 张宗德. 结核病患者外周血单个核细胞内环状RNA表达谱分析及诊断标识的鉴定[J]. 中国防痨杂志, 2025, 47(4): 460-470.
[3]	李敏, 姚宇珊, 乔海霞, 雷红. 肺结核与肠道菌群的相关性及治疗策略[J]. 中国防痨杂志, 2025, 47(4): 520-526.
[4]	石红雨, 张国良, 肖国辉. 单细胞转录组测序技术在结核病研究中的应用[J]. 中国防痨杂志, 2025, 47(3): 362-368.
[5]	《脊柱结核并发HIV/AIDS患者诊断及治疗专家共识》编写组, 中国防痨协会骨关节结核专业分会, 中国性病艾滋病防治协会艾滋病外科专业委员会, 中国西部骨结核联盟, 中国华北骨结核联盟. 脊柱结核并发HIV/AIDS患者诊断及治疗专家共识(第2版)[J]. 中国防痨杂志, 2025, 47(1): 1-11.
[6]	刘瑞花, 萨日娜, 王芙蓉. 肺癌与肺结核在疾病发生与发展中相互影响的研究进展[J]. 中国防痨杂志, 2025, 47(1): 102-111.
[7]	张国钦, 曲婷, 孟庆琳, 周林, 刘二勇. 我国结核病合并HIV/AIDS双重感染防治策略的实施进展[J]. 中国防痨杂志, 2025, 47(1): 12-17.
[8]	付宝慧, 张静. 冬虫夏草菌联合抗结核治疗肺结核的效果观察[J]. 中国防痨杂志, 2024, 46(S2): 52-54.
[9]	余翔, 王雪梅. 卷曲霉素联合左氧氟沙星治疗复治涂阳肺结核的疗效[J]. 中国防痨杂志, 2024, 46(S2): 104-105.
[10]	韦忠灵, 李志峰, 凌学敏, 蒙夏艳, 杨巧妙, 黄小霞, 何华伟. 支气管镜综合介入治疗对中央气道狭窄型支气管结核患者肺功能和免疫功能影响的观察[J]. 中国防痨杂志, 2024, 46(S2): 213-215.
[11]	张建桥, 刘玲俊, 陈丹华, 孔萍萍. 早期肠内营养护理在老年重症肺炎患者的应用效果[J]. 中国防痨杂志, 2024, 46(S2): 396-398.
[12]	仇丽萍. 非小细胞肺癌免疫相关生物标志物的研究进展[J]. 中国防痨杂志, 2024, 46(S2): 528-529.
[13]	吴国威, 王永存, 杨志雄. 肺动脉内膜肉瘤一例[J]. 中国防痨杂志, 2024, 46(S2): 548-550.
[14]	张德欣, 金烈. IgG4相关肾病合并肺部感染二例并文献复习[J]. 中国防痨杂志, 2024, 46(S2): 553-555.
[15]	曾坚, 王瑾, 方木通, 傅佳鹏, 卢水华. 12例艾滋病患者泌尿系结核的临床特征分析[J]. 中国防痨杂志, 2024, 46(S1): 33-36.